Main research findings

Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines of prior platinum-based chemotherapy. 2

A case of retinopathy associated with Fibroblast Growth Factor Receptor inhibitor (FGFRi) was reported in a patient treated with Erdafitinib. 1

Asinex-5082, an octahydropyrrolo[3,2-b]pyridin derivative, showed higher binding affinity to FGFR3 and lower binding affinity to VEGFR2 than Erdafitinib. 5

FGFR inhibitors are promising therapeutic agents for cancer treatment, but resistance and side effect profile may limit their clinical utility. 4

Reasons for side effects

FGFR inhibitors suppress cancer cell proliferation by inhibiting FGFR, but they can also affect normal cells. This can cause various side effects.

Common side effects

Nail abnormalities

FGFR inhibitors can cause nail abnormalities such as onycholysis. 3

Palmar-plantar erythrodysesthesia syndrome

FGFR inhibitors can cause palmar-plantar erythrodysesthesia syndrome. 3

Stomatitis

FGFR inhibitors can cause stomatitis. 3

Retinopathy

Erdafitinib can cause retinopathy. 1

Countermeasures for side effects

Nail abnormalities

If nail abnormalities occur, seek appropriate treatment such as nail trimming or topical medication.

Palmar-plantar erythrodysesthesia syndrome

If palmar-plantar erythrodysesthesia syndrome occurs, seek appropriate treatment such as using moisturizers or topical medication.

Stomatitis

If stomatitis occurs, seek appropriate treatment such as using oral medication for stomatitis or paying attention to diet.

Retinopathy

If retinopathy occurs, seek appropriate treatment such as adjusting the dosage of erdafitinib or stopping the medication.

Comparison between studies

Common points of studies

Multiple studies have shown that FGFR inhibitors are effective in treating urothelial cancer. In addition, various side effects have been reported to occur with FGFR inhibitor administration.

Differences between studies

The effectiveness and incidence of side effects of FGFR inhibitors vary depending on the study. This is thought to be due to differences in the characteristics of the patients and the research methods.

Precautions for applying to real life

FGFR inhibitors are effective drugs for the treatment of urothelial cancer, but you need to be aware of the risk of side effects. Consult your doctor if you experience side effects.

Limitations of current research

Current research has not provided sufficient data on the long-term safety and efficacy of FGFR inhibitors. Also, further research is needed to identify patients who benefit from FGFR inhibitors and to prevent the occurrence of side effects.

Future research directions

Clinical trials are needed to evaluate the long-term safety and efficacy of FGFR inhibitors. Also, research is needed to prevent side effects of FGFR inhibitors and to identify patients who benefit from FGFR inhibitors.

Conclusion

FGFR inhibitors are effective drugs for the treatment of urothelial cancer, but you need to be aware of the risk of side effects. Consult your doctor if you experience side effects. Further research, such as clinical trials evaluating the long-term safety and efficacy of FGFR inhibitors, is needed.